New combo approach may offer a better shot at controlling recurrent nose cancer

NCT ID NCT07129772

First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 28 times

Summary

This study tests whether giving immunotherapy (pembrolizumab) plus chemotherapy before and after surgery can improve outcomes for people whose nasopharyngeal cancer has returned locally. About 53 adults with recurrent cancer that hasn't spread will receive the drug combo, then undergo minimally invasive surgery to remove any remaining tumor, followed by maintenance immunotherapy. The goal is to see if this approach can achieve a complete disappearance of cancer cells and possibly reduce the need for lifelong treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CANCINOMA (NPC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Department of Clinical Oncology, Queen Mary Hospital

    Hong Kong, Hong Kong

Conditions

Explore the condition pages connected to this study.